-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
com" data-mpa-powered-by="yiban.
75em;">
75em;">
75em;">
75em;">
75em;">
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>com" style='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 Opdivo ® (Ou Diwo ® ) similar to a biological drug, LY01015, led according to a class of therapeutic biologicals 3.
3 Classified declared Opdivo ® (Ou Diwo ® ) of Biosimilars , LY01015 is the first biosimilar of Opdivo ® (Odivo ® )declared in accordance with the 3.
3 registration classification of therapeutic biological products.
®® isused to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, Patients with renal cell carcinoma, classic Hodgkin’s lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction. 5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.
Compared with traditional treatment methods, PD-1 inhibitors fight tumor cells by activating the body’s own immune system—blocking the pathway by which tumor cells induce T cells to "dormant" in human immune cells, thereby partially restoring the ability of T cells to kill tumor cells.
Function to achieve long-term control or elimination of tumors, bringing hope for the cure of cancer.
5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;text-align:center;">5em;">
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;color:#1773B2;">2em;">
5px;">
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
5px;color:#1773B2;">2em;">
5px;color:#1773B2;">2em;">5px;">
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products
At present, Boan Biological has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
Boan Bio has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
Boan Bio has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>com" style='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;letter-spacing:0px;">
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
75;letter-spacing:0px;">
75;letter-spacing:0px;">
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
com" style='margin:0px 0.
5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;">5em;">5em;">5em;">5em;">5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
，（LY01015），。
5px;line-height:1.75em;">
，（LY01015），。
5px;line-height:1.75em;">
，（LY01015），。
5px;line-height:1.75em;">
，（LY01015），。
5px;line-height:1.75em;">
，（LY01015），。
5px;line-height:1.75em;">
，（LY01015），。
，（LY01015），。
，（LY01015）（LY01015），。544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;'>
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>com" style='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
5px;color:#3E3E3E;line-height:2em;box-sizing:border-box ;"> LY01015 is the first biosimilar of Opdivo ® (Odivo ® ) declared in accordance with the 3.
3 registration classification of therapeutic biological products .
It is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, renal cell carcinoma, and typical Huo Patients with Qijin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction.
3 Opdivo ® (Ou Diwo ® ) similar to a biological drug, LY01015, led according to a class of therapeutic biologicals 3.
3 Classified declared Opdivo ® (Ou Diwo ® ) of Biosimilars , LY01015 is the first biosimilar of Opdivo ® (Odivo ® )declared in accordance with the 3.
3 registration classification of therapeutic biological products.
®® isused to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma, Patients with renal cell carcinoma, classic Hodgkin’s lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, and adenocarcinoma of the stomach or gastroesophageal junction. 5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>Tumor immunotherapy represented by PD-1 inhibitors has become one of the main methods of cancer treatment in China and even globally.
Compared with traditional treatment methods, PD-1 inhibitors fight tumor cells by activating the body’s own immune system—blocking the pathway by which tumor cells induce T cells to "dormant" in human immune cells, thereby partially restoring the ability of T cells to kill tumor cells.
Function to achieve long-term control or elimination of tumors, bringing hope for the cure of cancer.
5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;text-align:center;">5em;">
5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua, CEO of Boan Biotech, said:
5em 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;text-align:center;">5em;">5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua, CEO of Boan Biotech, said:
5em;">5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua, CEO of Boan Biotech, said:
5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua, CEO of Boan Biotech, said:
5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua, CEO of Boan Biotech, said:
5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;">Jiang Hua,5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;"> CEO of5px;text-align:center;box-sizing:border-box ;overflow-wrap:break-word ;"> Boan Bio, said:Jiang Hua, CEO of Boan Bio, said: Jiang Hua, CEO of Boan Bio, said: Jiang Hua, CEO of Boan Bio, said:com" style='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5px;color:#1773B2;">2em;">
5px;color:#1773B2;">2em;">
5px;">
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
5px;color:#1773B2;">2em;">
5px;color:#1773B2;">2em;">5px;">
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products .
We are optimistic about the market prospects of LY01015 and plan to carry out the registration of the drug in other countries and regions in the world outside the Chinese market.
The company is intensively advancing the research and development process of drug candidates in the research and development pipeline, and looks forward to benefiting more patients in need in China and the world by providing high-quality and affordable biological antibody products
5em;padding:0px;max-width:100%;clear:both;min-height:1em;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;'> As one of the business focus of the Group's development, Luye Pharmaceuticals is continuing to increase its investment in the research and development of biological drugs, and through Boan Biopharmaceuticals to accelerate the global deployment of biological drugs.
At present, Boan Biological has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
At present, Boan Biological has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
Boan Bio has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
Boan Bio has built a product portfolio of more than 10 innovative antibodies with international intellectual property protection and 8 biosimilar drugs, and is actively deploying in cutting-edge technology fields such as cell therapy.
5em;padding:0px;max-width:100%;clear:both;min-height:1em;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;text-align:center;box-sizing:border-box ;'>
5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>com" style='margin:0px;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
About Boan Bio
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;letter-spacing:0px;">
About Boan Bio
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
About Boan Bio
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
About Boan Bio
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
About Boan Bio
5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">
75;letter-spacing:0px;">
About Boan Bio
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">75;letter-spacing:0px;">
About Boan Bio
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">75;letter-spacing:0px;">
About Boan Bio
5em 5px 0px 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;width:12px;height:12px;border-width:1px;border-style:solid;border-color:#1773B2;display:inline-block;vertical-align:top;background-color:#1773B2;color:#1773B2;">75;letter-spacing:0px;">About Boan Bio
About Boan Bio
About Boan BioAbout Boan Bio5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">5em 0px;padding:0px;max-width:100%;box-sizing:border-box ;overflow-wrap:break-word ;">75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75;color:#3E3E3E;letter-spacing:0px;">75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
75em;">Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
Boan Bio is a subsidiary of Luye Pharmaceutical Group.
It was established in 2013.
It is a comprehensive biopharmaceutical company specializing in the development of therapeutic antibodies, focusing on oncology, autoimmune, pain and endocrine diseases.
The company's antibody discovery activities revolve around four major platforms, namely, fully human antibody transgenic mouse phage display technology, bispecific T-cell Engager technology platform, antibody coupling (ADC) technology platform, and nano antibody platform.
Boan Bio has a complete integrated industrial chain from antibody production and lead optimization, cell line establishment and process development, technology transfer, pilot production and commercial production.
In addition, the company is also actively deploying around cutting-edge technologies.
Its cell therapy products use non-viral vectors to prepare advanced solid tumor CAR-Ts, and deploy a new generation of universal and controllable CAR-Ts to rapidly develop safer, effective, and affordable CAR-Ts.
CAR-T products.
In addition to China, Boan Bio is also engaged in the development of biological products in the US and EU markets.
com" style='margin:0px 0.
5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;box-sizing:border-box ;overflow-wrap:break-word ;'>5em;">5em;">5em;">5em;">5em;">5em;padding:0px;max-width:100%;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:1.
75em;box-sizing:border-box ;overflow-wrap:break-word ;'>
5em;padding:0px;max-width:100%;clear:both;min-height:1em;color:#333333;font-family:-apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size:17px;letter-spacing:0.
544px;white-space:normal;background-color:#FFFFFF;text-align:center;box-sizing:border-box ;'>
